文献速递传染病防控与疫情报告免疫规划慢病防控与筛查

美国65岁及以上门诊COVID-19患者抗病毒处方领取情况(2023年6月至2025年9月)

COVID-19 Antiviral Prescription Receipt Among Outpatients Aged ≥65 Years - United States, June 1, 2023-September 30, 2025.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2026-02-19

基于Truveta去标识电子健康记录数据的多因素logistic回归分析,评估2023年6月至2025年9月美国65岁及以上门诊COVID-19患者抗病毒处方领取的影响因素。结果显示不同季节处方率在16%至38%之间波动,2024年春季为21%、2024-25年秋冬季为23%、2025年春季为16%、2025年夏季为19%,低于其他季节的37%-38%;接种过至少1剂COVID-19疫苗者领取处方的比值更高(aOR=1.73)。提示该人群抗病毒药物可能存在处方不足。

要点

  • 65岁及以上门诊COVID-19患者抗病毒处方率在2025年春季仅16%,明显低于其他季节的37%-38%。
  • 已领取处方者中99%在检测阳性或诊断后7天内领取,80%为奈玛特韦/利托那韦。
  • 接种至少1剂COVID-19疫苗者领取抗病毒处方的比值更高(aOR=1.73)。

核心结论

  • 65岁及以上成人COVID-19抗病毒处方可能存在不足,且处方率随时间变化。
  • 鼓励该人群每年接种COVID-19疫苗并提高抗病毒处方率,或可降低重症和住院风险。

研究设计与样本

  • 对Truveta实时去标识电子健康记录数据进行多因素logistic回归分析。
  • 研究对象为2023年6月1日至2025年9月30日在门诊就诊、SARS-CoV-2检测阳性或诊断为COVID-19的65岁及以上成人。

主要发现

  • 2024年春季处方率为21%、2024-25年秋冬季为23%、2025年春季为16%、2025年夏季为19%,均低于其他季节的37%-38%。
  • 领取处方者中99%在检测阳性或诊断后7天内领取,80%处方为奈玛特韦/利托那韦。
  • 75-84岁和≥85岁者领取处方的aOR分别为1.09和1.11,亚裔为1.42,西班牙裔或拉丁裔为1.24,接种至少1剂疫苗者为1.73。
  • 至少有一种合并症者和农村居民领取抗病毒处方的比值较低。
  • 2024年夏季领取处方的aOR为1.05,高于其他分析时段;COVID-19发病率较低时段处方比值较低。

临床怎么用

  • 对65岁及以上门诊COVID-19患者,应评估抗病毒治疗指征并及时处方,尤其在处方率较低的季节。
  • 可结合疫苗接种史识别抗病毒处方不足的高风险人群,并关注合并症患者和农村居民。
  • 处方应尽量在检测阳性或诊断后7天内完成,以符合用药时机。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adults aged ≥65 years have the highest rates of COVID-19-related hospitalization. Despite the proven benefit of COVID-19 antivirals in preventing severe outcomes, data suggest that their use is low among older adults. To assess factors associated with receipt of an antiviral prescription among adults aged ≥65 years examined in outpatient settings who received a positive SARS-CoV-2 test result or COVID-19 diagnosis during June 1, 2023-September 30, 2025, multivariate logistic regression analysis of Truveta real-time deidentified electronic health record data was performed. The percentage of COVID-19 outpatients aged ≥65 years who received an antiviral prescription was lower in spring 2024 (21%), fall-winter 2024-25 (23%), spring 2025 (16%), and summer 2025 (19%) than during other seasons (range = 37%-38%). Among those persons who received a prescription, 99% received it within 7 days of a positive SARS-CoV-2 test result or COVID-19 diagnosis, and 80% were prescribed nirmatrelvir/ritonavir. Among adults aged ≥65 years, the odds of receiving an antiviral prescription were higher among those aged 75-84 and ≥85 years (adjusted odds ratio [aOR] = 1.09 and 1.11, respectively), Asian (aOR = 1.42) or Hispanic or Latino persons (aOR = 1.24), and those who had received ≥1 COVID-19 vaccine dose (aOR = 1.73) than among adults in other age, racial, ethnic, and vaccination status groups. Persons with at least one comorbidity and rural residents had lower odds of receiving an antiviral prescription. Persons with COVID-19 had higher odds of receiving a COVID-19 antiviral prescription in summer 2024 (aOR = 1.05) compared with other analytic periods. Odds of prescribing were lower during periods of lower COVID-19 incidence. Antivirals might be underprescribed among adults aged ≥65 years, and prescribing rates vary temporally. Encouraging annual COVID-19 vaccination and increased prescribing of antivirals among adults aged ≥65 years with COVID-19 could reduce the risk for severe illness and hospitalization in this population.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Raykin J, Rochin I, Wiegand R, et al. COVID-19 Antiviral Prescription Receipt Among Outpatients Aged ≥65 Years - United States, June 1, 2023-September 30, 2025. MMWR Morb Mortal Wkly Rep. 2026. PMID: 41712466. doi:10.15585/mmwr.mm7506a1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。